The 36-month beta value for BFRI is at 0.43. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BFRI is 8.07M, and currently, shorts hold a 4.38% of that float. The average trading volume for BFRI on July 09, 2025 was 172.61K shares.
BFRI) stock’s latest price update
The stock of Biofrontera Inc (NASDAQ: BFRI) has increased by 14.43% when compared to last closing price of $0.73.Despite this, the company has seen a gain of 21.25% in its stock price over the last five trading days. globenewswire.com reported 2025-06-30 that Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% – 35% of net sales.
BFRI’s Market Performance
BFRI’s stock has risen by 21.25% in the past week, with a monthly rise of 39.03% and a quarterly rise of 15.86%. The volatility ratio for the week is 9.56% while the volatility levels for the last 30 days are 9.08% for Biofrontera Inc The simple moving average for the last 20 days is 25.52% for BFRI’s stock, with a simple moving average of -7.37% for the last 200 days.
BFRI Trading at 25.14% from the 50-Day Moving Average
After a stumble in the market that brought BFRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.42% of loss for the given period.
Stock Fundamentals for BFRI
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.55 for the gross margin
The net margin for Biofrontera Inc stands at -0.3. The total capital return value is set at -2.89. Equity return is now at value -384.98, with -56.00 for asset returns.
Based on Biofrontera Inc (BFRI), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -2.27. The debt to equity ratio resting at 10.37. The interest coverage ratio of the stock is 4.57.
Currently, EBITDA for the company is -14.44 million with net debt to EBITDA at -0.2. When we switch over and look at the enterprise to sales, we see a ratio of 0.29. The receivables turnover for the company is 9.42for trailing twelve months and the total asset turnover is 2.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In conclusion, Biofrontera Inc (BFRI) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
